Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  busulfan
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 122 for your search:
Start Over
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 6 months to less than 18 years
Sponsor: Other
Protocol IDs: ALL SCTped FORUM 2012, NCT01949129
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000068608, EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, EU-20213, AEWS0331, NCT00020566
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 20 at diagnosis
Sponsor: Other
Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC-FludT.14/L, EudraCT-No.: 2008-002356-18, NCT00822393
Study in Localized and Disseminated Ewing Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: 108128, EudraCT number: 2008-003658-13, NCT00987636
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
Busulfan Plus Melphalan Versus Melphalan
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2010-0071, NCI-2011-02760, NCT01413178
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581
Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CBMTC-AML-1, NCT01751997
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: GuangXi-AML- HSCT-2012-07, NCT01766375
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: GEM2012MENOS65, NCT01916252
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 and younger
Sponsor: Other
Protocol IDs: ISG/AIEOP EW-1, NCT02063022
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 1999LS073, MT1999-20, 9911M24961, NCT00167219
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Start Over